Clinical effect of Fuhe Beihua prescription combined with transcatheter arterial chemoembolization in treatment of primary liver cancer patients with liver depression and spleen deficiency: An analysis of 218 cases

Jiang RuiYuan; Rong Zhen; Man TingTing; Tan YanChun; Liu QiuYue; Mo ChunMei

doi:10.3969/j.issn.1001-5256.2020.10.012

Volume 36 Issue 10

Oct. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(10): 2219-2225

PDF( 317 KB)

Clinical effect of Fuhe Beihua prescription combined with transcatheter arterial chemoembolization in treatment of primary liver cancer patients with liver depression and spleen deficiency: An analysis of 218 cases

DOI: 10.3969/j.issn.1001-5256.2020.10.012

Graduate School,Guangxi University of Chinese Medicine
Department of Oncology,The First Affiliated Hospital of Guangxi University of Chinese Medicine
Second Inpatient Area,Department of Hepatology,The First Affiliated Hospital of Guangxi University of Chinese Medicine

Research funding:

Received Date: 2020-04-12
Published Date: 2020-10-20

Abstract

Abstract

Objective To investigate the clinical effect of Fuhe Beihua prescription combined with transcatheter arterial chemoembolization( TACE) in the treatment of primary liver cancer patients with liver depression and spleen deficiency and its effect on T lymphocyte subsets.Methods A retrospective analysis was performed for the clinical data of stage Ⅲ primary liver cancer patients with liver depression and spleen deficiency who were treated in Department of Hepatology and Department of Oncology in The First Affiliated Hospital of Guangxi University of Chinese Medicine from January 2018 to January 2020. According to whether the traditional Chinese medicine Fuhe Beihua prescription was used,the patients were divided into treatment group( treated with routine TACE and oral administration of Fuhe Beihua prescription) and control group( treated with routine TACE alone),and the course of treatment was 16 weeks for both groups. The two groups were compared in terms of short-term response rate,quality-of-life score,serum alpha-fetoprotein( AFP) level,four indicators of liver fibrosis,coagulation function parameters,peripheral blood T lymphocyte subsets,and liver function parameters. The independent samples t-test was used for comparison of continuous data between two groups,and the chi-square test was used for comparison of categorical data between two groups. A repeated-measures analysis of variance was used for comparison of continuous data between different groups at different time points. Results A total of 218 patients were selected,with 118 in the control group and 100 in the treatment group. The treatment group had an objective response rate of 33% and a disease control rate of 66% at week 8 of treatment and an objective response rate of 34%and a disease control rate of 69% at week 16 of treatment,and the control group had an objective response rate of 26. 27% and a disease control rate of 68. 64% at week 8 of treatment and an objective response rate of 30. 51% and a disease control rate of 68. 64% at week 16 of treatment; there was a significant difference in objective response rate between the two groups at weeks 8 and 16 of treatment( P < 0. 05).Both groups had significant increases in Karnofsky Performance Scale( KPS) score,fibrinogen,and albumin( Alb) from before treatment to weeks 8 and 16 of treatment( all P < 0. 05),and there were significant differences in KPS score,fibrinogen,and Alb between the two groups at weeks 8 and 16 of treatment( all P < 0. 05). Both groups had significant reductions in AFP,the four indicators of liver fibrosis,alanine aminotransferase( ALT),aspartate aminotransferase( AST),prothrombin time( PT),and traditional Chinese medicine( TCM) syndrome score after treatment( all P < 0. 05),and at weeks 8 and 16 of treatment,there were significant differences between the two groups in AFP,the four indicators of liver fibrosis,ALT,AST,PT,and TCM syndrome score( all P < 0. 05). At weeks 8 and 16 of treatment,the treatment group had significant increases in the levels of CD3+,CD4+,and CD4+/CD8+( all P < 0. 05) and a significant reduction in the level of CD8+( P < 0. 05),and there were significant differences in the levels of T lymphocyte subsets between the two groups at weeks 8 and16 of treatment( all P < 0. 05). Conclusion Fuhe Beihua prescription combined with routine TACE has a better clinical effect than TACE alone in the treatment of primary liver cancer patients with liver depression and spleen deficiency,possibly by regulating the levels of T lymphocyte subsets.
- liver neoplasms,
- chemoembolization,therapeutic,
- Fuhe Beihua Decoction,
- retrospective studies

FullText(HTML)

References(19)

References

[1] Global Burden of Disease Cancer Collaboration,FITZMAURICE C,ABATE D,et al. Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to2017:A systematic analysis for the global burden of disease study[J]. JAMA Oncol,2019,5(12):1749-1768.

[2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[3] CHEN YD,MO CM,RONG Z,et al. Research Advance of Traditional Chinese Medicine Combined Transcatheter Arterial Chemoembolization(TACE)in Treating Primary Hepatic Carcinoma[J]. J Liaoning Univ Tradit Chin Med,2019,21(1):87-90.(in Chinese)陈亚栋，莫春梅，荣震，等．中药联合肝动脉栓塞化疗术(TACE)治疗原发性肝癌研究进展[J]．辽宁中医药大学学报，2019,21(1):87-90.

[4] CHEN XY. Effect of Fuhe Beihua Decoction on T-lymphocyte subsets and NK cells after chemoembolization for primary liver cance[D]. Nanjing:Guangxi University of Chinese Medicine,2016.(in Chinese)陈小云．敷和备化方对原发性肝癌化疗栓塞术后T淋巴细胞亚群及NK细胞的影响[D]．南宁:广西中医药大学，2016.

[5] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.

[6] LIN HS. Guidelines for traditional chinese medicine diagnosis and treatment of malignant tumors(2014 edition)[M]. Beijing:People’s Medical Publishing House,2014:372-400.(in Chinese)林洪生．恶性肿瘤中医诊疗指南(2014版)[M]．北京:人民卫生出版社，2014:372-400.

[7] ZHANG Q,LI HP. Clinical analysis of TACE combined with RFA in treating primary liver cancers of high-risk sites[J/CD]. Chin J Oper Proc Gen Surg(Electronic Version),2020,14(2):201-204.(in Chinese)张强，李恒平．TACE术联合RFA术对高危部位原发性肝癌的临床疗效分析[J/CD]．中华普外科手术学杂志(电子版)，2020,14(2):201-204.

[8] XU W,LI GF,LI Q,et al. New clinical advances in tumor heterogeneity of hepatocellular carcinoma[J]. J Hepatopancreatobiliary Surg,2016,28(1):84-86.(in Chinese)徐伟，李高峰，李权，等．肝癌肿瘤异质性的临床新进展[J]．肝胆胰外科杂志，2016,28(1):84-86.

[9] CHANG QQ,PENG Y,WANG GJ,et al. Clinical research progress of small molecule tyrosine kinase inhibitors as antihepatocellular carcinoma agents[J]. Chin J Clin Pharmacol Ther,2019,24(8):948-956.(in Chinese)常青青，彭英，王广基，等．抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]．中国临床药理学与治疗学，2019,24(8):948-956.

[10] ZHAO BK,HE L,WU ZT,et al. Clinical efficacy of a regimen containing retetrexed in the treatment of advanced hepatocellular carcinoma by TACE[J/OL]. J Chin Oncol. http://kns.cnki. net/kcms/detail/33. 1266. R. 20200228. 1135. 018. html.(in Chinese)赵宝魁，贺莉，吴泽涛，等．含雷替曲塞方案经TACE治疗中晚期肝癌的临床疗效[J/OL]．肿瘤学杂志．http://kns. cnki. net/kcms/detail/33. 1266. R. 20200228. 1135. 018. html.

[11] CHEN H,MAO JP. The research progress on tumor immune escape built in relations of tumor and T lymphocytes[J]. China Biotechnol,2012,32(10):86-92.(in Chinese)陈海，毛建平．肿瘤免疫逃逸与T淋巴细胞关系的研究进展[J]．中国生物工程杂志，2012,32(10):86-92.

[12] ZHU Y,QIN LX. Recent progress of biological immunotherapy for hepatocellular carcinoma[J]. Chin J Pract Surg,2016,36(6):636-640.(in Chinese)朱迎，钦伦秀．肝癌免疫生物治疗的现状及评价[J]．中国实用外科杂志，2016,36(6):636-640.

[13] WAN H,ZHANG XX. Progress in immunotherapy for T-lymphocyte-associated tumors[J]. China Pharmacy,2017,28(20):2872-2876.(in Chinese)万红，张晓旭．T淋巴细胞相关肿瘤免疫疗法的研究进展[J]．中国药房，2017,28(20):2872-2876.

[14] WANG LJ,MIAO TG,NING GX,et al. The influence of TACE on T lymphocyte subsets in patients with primary liver cancer[J]. J Intervent Radiol,2015,24(2):165-168.(in Chinese)王立静，苗同国，宁更献，等．肝动脉化疗栓塞术对原发性肝癌患者T淋巴细胞亚群的影响[J]．介入放射学杂志，2015,24(2):165-168.

[15] DING H,WANG J,WANG ZG,et al. Clinical effectiveness of cantharidin-containing Chinese medicine preparations on immune function in patients with hepatocellular cancer:A metaanalysis[J]. J Oncol Chin Med,2020,2(1):85-91.(in Chinese)丁皓，王婧，王志刚，等．含斑蝥素中药制剂对肝癌患者免疫功能影响的Meta分析[J]．中医肿瘤学杂志，2020,2(1):85-91.

[16] HE S,LIAO ZX. Research progress on the mechanism of traditional Chinese medicine in the treatment of hepatocellular carcinoma[J]. Chin Tradit Patent Med,2017,39(1):155-160.(in Chinese)贺珊，廖长秀．中药治疗肝癌机制的研究进展[J]．中成药，2017,39(1):155-160.

[17] HUANG RR,QIAN Y,XIANG M. Advances in immunomodulatory effects of ginsenoside Rh2[J]. Chin J Immunol,2019,35(23):2936-2941.(in Chinese)黄容容，钱颖，向明．人参皂苷Rh2免疫调节作用研究进展[J]．中国免疫学杂志，2019,35(23):2936-2941.

[18] XIAO Y,WU ZP,JIN CG. Inhibitory effect of ethanol extract of Oldenlandia Diffusa on colorectal cancer angiogenesis in BALB/c mice[J]. J Kunming Med Univ,2013,34(10):53-57.(in Chinese)肖云，伍治平，金从国．白花蛇舌草提取物抗小鼠结直肠癌血管生成的实验研究[J]．昆明医科大学学报，2013,34(10):53-57.

[19] REN ZJ. Matrine induces autophagy in human hepatoma HepG2cells through m TOR signaling pathway[D]. Lanzhou:Lanzhou University,2011:7-9.(in Chinese)任志俭．苦参碱通过m TOR信号通路诱导人肝癌HepG2细胞发生自噬现象[D]．兰州:兰州大学，2011:7-9.

Relative Articles

[1]	WANG WenHui, DUAN XuHua, LI Hao, LI FengYao, JU ShuGuang, WANG ManZhou, REN JianZhuang, HAN XinWei. Effect of arsenic trioxide-loaded CalliSpheres beads in the treatment of rabbits with VX2 liver tumor[J]. Journal of Clinical Hepatology, 2020, 36(12): 2730-2734. doi: 10.3969/j.issn.1001-5256.2020.12.018
[2]	Cai MiaoTian, Liang LianChun. Pathogen distribution and drug resistance in liver cancer patients with liver abscess after transarterial chemoembolization or ablation[J]. Journal of Clinical Hepatology, 2020, 36(1): 118-122. doi: 10.3969/j.issn.1001-5256.2020.01.026
[3]	Zhou LinFeng, Wang WanSheng, Zhu XiaoLi, Li WanCi, Tang HaoHuan. Feasibility, safety, and clinical effect of establishing a green channel for the treatment of cirrhotic portal hypertension with esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2019, 35(5): 996-1001. doi: 10.3969/j.issn.1001-5256.2019.05.013
[4]	Ma MingYuan, Lin GangYi, Cai ZongYang, Luo HeSan, Wu ShengXi. Efficacy and safety of microsphere transarterid chemoembolization combined with radiotherapy versus microsphere transarterial chemoembolization alone in treatment of patients with unresectable liver cancer[J]. Journal of Clinical Hepatology, 2019, 35(11): 2489-2494. doi: 10.3969/j.issn.1001-5256.2019.11.020
[5]	Wang Hui, Pan YuGuo, Xia JinTang, Zhou MiMi, Cai Chun. Clinical effect of transcatheter arterial chemoembolization in treatment of primary liver cancer: application and research advances[J]. Journal of Clinical Hepatology, 2018, 34(2): 414-418. doi: 10.3969/j.issn.1001-5256.2018.02.044
[6]	Li CuiCui, Ma JingTing, Zhou He, Hu RongRong, Wang Kai, Li DongFu. Antiviral therapy using sofosbuvir combined with ribavirin after transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma with tumor thrombus in the right atrium: a case report[J]. Journal of Clinical Hepatology, 2018, 34(1): 168-171. doi: 10.3969/j.issn.1001-5256.2018.01.035
[7]	Wu Jian, Yin Fang, Luo GuanHong, Zheng YangYang, Li Hong, Zhu ShaoHua, Zhang Jing, Zhou XinMin. Clinical effect and safety of transarterial chemoembolization combined with apatinib in treatment of advanced primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(4): 775-778. doi: 10.3969/j.issn.1001-5256.2018.04.016
[8]	Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
[9]	Yu Tong, Zhai XiaoFeng, Liu Qun, Meng YongBin, Lu JianYing, Chen Zhe. Clinical effect and safety of hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization in treatment of Barcelona Clinic Liver Cancer stage C primary liver cancer[J]. Journal of Clinical Hepatology, 2017, 33(2): 281-285. doi: 10.3969/j.issn.1001-5256.2017.02.015
[10]	Zheng Kang, He MengGuo, Wang ZhiXiang. Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(5): 899-903. doi: 10.3969/j.issn.1001-5256.2016.05.017
[11]	Lu: TianShi, Zou YingHua, Wang Jian, Song Li. Current status of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(1): 49-55. doi: 10.3969/j.issn.1001-5256.2016.01.007
[12]	Sun Wei, Ding XiaoYan, Chen JingLong. Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations[J]. Journal of Clinical Hepatology, 2016, 32(12): 2337-2341. doi: 10.3969/j.issn.1001-5256.2016.12.021
[13]	Zhu Yun, Wang RuiLin, Sun XueYing, Yu SiMiao, Jing Jing, Wang JiaBo, He TingTing, Huang YiXue, Wang LiPing, Sun YongQiang. Guiding significance of Guideline for diagnosis and treatment of herb-induced liver injury in clinical diagnosis: a retrospective analysis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2159-2162. doi: 10.3969/j.issn.1001-5256.2016.11.032
[14]	Wang BaoXin, Wu ZhenMing, Zhang Rui, Hu XinHua, Zou QingHua, Fan YiFeng, Xing HongJian, Xiao FangFang, Qi XiuHeng. Intervention of raltitrexed combined with epirubicin in hepatic arterial infusion and embolization in treatment of primary liver cancer[J]. Journal of Clinical Hepatology, 2015, 31(5): 725-728. doi: 10.3969/j.issn.1001-5256.2015.05.022
[15]	Hu CaiXia, Zheng JiaSheng, Cui ShiChang, Qian ZhiLing. Efficacy of nutritional intervention in patients with primary hepatocellular carcinoma treated by transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2015, 31(4): 569-572. doi: 10.3969/j.issn.1001-5256.2015.04.022
[16]	Yin Hao, Xiao Lin, Zhan XinYu, Zhang ZeGao, Lu XiaoBo, Zhang YueXin. Prognostic factors in patients with hepatitis B- related primary liver cancer treated with transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2014, 30(1): 50-54. doi: 10.3969/j.issn.1001-5256.2014.01.011
[17]	Zhou ZhenDong, Zhang LeMing, Wang TingTing, Sun XiaoKe, Chen LiangLiang, Liu Kui. Meta-analysis of transarterial chemoembolization combined with microwave coagulation therapy in treatment of advanced liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(8): 591-595. doi: 10.3969/j.issn.1001-5256.2013.08.010
[18]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[19]	Zhan GuoQing, Tan HuaBing, Zhu Lin, Li RuGui, Zhang WeiWei, Hu Bo, Du WeiXing. Antiviral effects of transcatheter hepatic arterial chemoembolization on middle and advanced stage hepatitis B virus-related liver cancer[J]. Journal of Clinical Hepatology, 2010, 26(4): 423-424+431.
[20]	Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	毛堂友，姚树坤，白宇宁，谢春娥，李晓红，李军祥. 胆石症中西医结合诊疗专家共识(2025年). 中国中西医结合消化杂志. 2025(03): 242-251 .
2.	吴凤娟，陈静，赵亚楠，刘娜，张雅菲，王东芳. 超声内镜和腹部超声诊断胆管结石的效能对比. 内科. 2024(04): 397-401 .
3.	王婷，董蕾，马师洋，赵刚，秦斌，薛琼，史海涛. 超声内镜在胆总管扩张病因鉴别诊断中的价值. 胃肠病学和肝病学杂志. 2024(11): 1525-1529 .
4.	许灿，周鹏哲，朱宁，穆维娜. 超声内镜与磁共振胰胆管成像对胆总管泥沙样结石的诊断价值. 中华消化病与影像杂志(电子版). 2023(05): 359-362 .
5.	于文昊，任利，王海久，王志鑫，孔繁玉，樊海宁. 超声内镜检查在胆胰壶腹疾病诊断中的应用. 中华消化外科杂志. 2023(12): 1414-1418 .
6.	张朋飞，梁荔，张明，邢国强，牛帅，逄淑东，安伟. 三维重建联合超声内镜检查在胆道肿瘤术前精准评估中的应用价值. 中华消化外科杂志. 2023(12): 1490-1494 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1214) PDF downloads(155)

Clinical effect of Fuhe Beihua prescription combined with transcatheter arterial chemoembolization in treatment of primary liver cancer patients with liver depression and spleen deficiency: An analysis of 218 cases

DOI: 10.3969/j.issn.1001-5256.2020.10.012